Assessment of the global opportunity for novel biomarkers for atrial fibrillation diagnosis – Evaluation of the Chinese landscape

Goal

Our client aimed to assess the global opportunity of novel biomarkers in AF for a) stroke and bleeding and b) recurrence risks in 8 global key markets, including China.
The results of the assessment would contribute to the go / no-go decision to pursue the R&D of these assets.

Approach

Understand diagnosis from a clinical angle, develop high-level VP & payer materials

Collect country insights via local KOL PMR, test all intended uses. Tailored to countries, leverage KOL insights & internal knowledge.

Validate & gather additional insights

Confirm and refine learnings via interviews with regional and local payers, lab directors and KOLs.

Consolidate results & delivery

Consolidate learnings on a global report and include China specific section and strategy

Supported the client’s go / no-go decision to pursue the R&D of these assets by:
1. Offering a clear view of the market size and price potential to support forecasting
2. Characterizing market appetite, readiness and likelihood of adoption to support R&D decisions
Deliverables included a comprehensive evidence strategy to align with market demands and position assets for success, as well as an in-depth market access and reimbursement analysis to optimize access and overcome reimbursement hurdles

Contact our experts

Philippe Coune

Partner

Miliyun Chiu

Senior Consultant

Charlotte Ng

Senior Consultant

Yin Sing Ng

Senior Consultant

Learn more about our China CoE

Our China Center of Excellence

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.